Sevasemten

Sevasemten is an orally active, selective allosteric inhibitor of skeletal muscle myosin that protects skeletal muscle from contraction-induced injury. Sevasemten decreases muscle damage biomarkers and fibrosis while increasing muscle strength and activity in in Duchenne muscular dystrophy disease models[1][2][3][4].

Product Specifications

CAS Number

[2417395-15-2]

Product Name Alternative

EDG-5506

UNSPSC

12352005

Target

Myosin

Type

Reference compound

Related Pathways

Cytoskeleton

Applications

Neuroscience-Neuromodulation

Field of Research

Others

Assay Protocol

https://www.medchemexpress.com/sevasemten.html

Purity

99.32

Solubility

DMSO : 250 mg/mL (ultrasonic)

Smiles

O=C1C=CC(C2=CN=C(OCC(F)(F)F)N=C2)=NN1CC3=CC(F)=CN=C3

Molecular Formula

C16H11F4N5O2

Molecular Weight

381.28

References & Citations

[1]Russell Alan, et al. Preparation of substituted pyridazinones for use in the treatment of neuromuscular diseases: World Intellectual Property Organization, WO2021231615. 2021-11-18.|[2]WHO Drug Information-World Health Organization (WHO) .|[3]Donovan J, et al. 351P Sevasemten, a fast myosin inhibitor, in adults with Becker muscular dystrophy results in reduced muscle damage biomarkers and functional stabilization[J]. Neuromuscular Disorders, 2024, 43: 104441.682.|[4]Russell AJ, et al., Modulating fast skeletal muscle contraction protects skeletal muscle in animal models of Duchenne muscular dystrophy. J Clin Invest. 2023 May 15;133 (10) :e153837.